Different effects of corticotropin-releaswing factor and urocortin 2 on apoptosis of prostate cancer cells in vitro

Journal of Molecular Endocrinology

Volumn 47, Issue 2, 2011, Pages 219-227

  Jin, Lai ^a   Zhang, Qichun ^a   Guo, Rui ^a   Wang, Lina ^a   Wang, Juejin ^a   Wan, Rong ^a   Zhang, Rongjian ^a   Xu, Youhua ^a   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTALARMIN; ANTISAUVAGINE 30; CASPASE 9; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; UROCORTIN II;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CHROMONES; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOBLOTTING; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MORPHOLINES; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; UROCORTINS;

EID: 80054795096     PISSN: 09525041     EISSN: 14796813     Source Type: Journal    
DOI: 10.1530/JME-11-0048     Document Type: Article

References (38)

1. Arcuri F, Cintorino M, Florio P, Floccari F, Pergola L, Romagnoli R, Petraglia F, Tosi P & Teresa Del Vecchio M 2002 Expression of Urocortin mRNA and peptide in the human prostate and in prostatic adenocarcinoma. Prostate 52 167-172. (doi:10.1002/pros. 10094)
2. Baley PA, Yoshida K, Qian W, Sehgal I & Thompson TC 1995 Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. Journal of Steroid Biochemistry and Molecular Biology 52 403-413. (doi:10.1016/0960-0760(95) 00001-G)
3. Belkhiri A, Dar AA, Zaika A, Kelley M & El-Rifai W 2008 t-Darpp promotes cancer cell survival by up-regulation of Bcl2 through Akt-dependent mechanism. Cancer Research 68 495-503. (doi:10.1158/0008-5472.CAN-07-1580)
4. Brar BK, Chen A, Perrin MH & Vale M 2007 Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2 beta by the CRF/Urocortin family of peptides. Endocrinology 145 1718-1729. (doi:10.1210/en.2003-1023)
5. Cai Y, Lee YF, Li G, Liu S, Bao BY, Huang J, Hsu CL & Chang C 2008 A new prostate cancer therapeutic approach: combination of androgen ablation with COX-2 inhibitor. International Journal of Cancer 123 195-201. (doi:10.1002/ijc.23481)
6. Chanalaris A, Lawrence KM & Townsend PA 2005 Hypertrophic effects of Urocortin homologous peptides are mediated via activation of the Akt pathway. Biochemical and Biophysical Research Communications 328 442-448. (doi:10.1016/j.bbrc.2005.01. 001)
7. Chatzaki E, Lambropoulou M, Constantinidis TC, Papadopoulos N, Taché Y, Minopoulos G & Grigoriadis DE 2006 Corticotropinreleasing factor (CRF) receptor type 2 in the human stomach: protective biological role by inhibition of apoptosis. Journal of Cellular Physiology 209 905-911. (doi:10.1002/jcp.20792)
8. Chaudhary KS, Abel PD & Lalani EN 1999 Role of the Bcl-2 gene family in prostate cancer progression and its implications for therapeutic intervention. Environmental Health Perspectives 107 49-57. (doi:10.2307/3434471)
9. Cunha GR, Donjacour AA, Cooke PS, Mee S, Bigsby RM, Higgins SJ & Sugimura Y 1987 The endocrinology and developmental biology of the prostate. Endocrine Reviews 8 338-362. (doi:10.1210/edrv-8-3-338)
10. Fukuda T, Takahashi K, Suzuki T, Saruta M, Watanabe M, Nakata T & Sasano H 2005 Urocortin1, Urocortin3/stresscopin, and corticotropin-releasing factor receptors in human adrenal and its disorders. Journal of Clinical Endocrinology and Metabolism 90 4671-4678. (doi:10.1210/jc.2005-0090)
11. Graziani G, Tentori L, Portarena I, Barbarino M, Tringali G, Pozzoli G & Navarra P 2002 CRH inhibits cell growth of human endometrial adenocarcinoma cells via CRH-receptor 1-mediated activation of cAMP-PKA pathway. Endocrinology 143 807-813. (doi:10.1210/en. 143.3.807)
12. Hockenbery D, Nunez G, Milliman C, Schreiber RD & Korsmeyer SJ 1990 Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 334-336. (doi:10.1038/348334a0)
13. Huang M, Kempuraj D, Papadopoulou N, Kourelis T, Donelan J, Manola A & Theoharides TC 2009 Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kB activation. Journal of Molecular Endocrinology 42 397-405. (doi:10.1677/JME-08-0120)
14. Jan-Erik D & Gunnar A 2008 Prostate cancer. Lancet 371 1710-1721. (doi:10.1016/S0140-6736(08)60729-1)
15. Kaprara A, Pazaitou-Paanayiotou K, Kortsaris A & Chatzaki E 2010 The corticotropin releasing factor system in cancer: expression and pathophysiological implications. Cellular and Molecular Life Sciences 67 1293-1306. (doi:10.1007/s00018-010-0265-2)
16. Kehinde EO, Maghrebi MA & Anim JT 2008 The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Canadian Journal of Urology 15 3967-3974.
17. Kuida K 2000 Caspase-9. International Journal of Biochemistry & Cell Biology 32 121-124. (doi:10.1016/S1357-2725(99)00024-2)
18. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W et al. 2001 Identification of Urocortin III, an additional member of the corticotropinreleasing factor (CRF) family with high affinity for the CRF2 receptor. PNAS 98 7570-7575. (doi:10.1073/pnas.121165198)
19. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES & Wang X 1997 Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91 479-489. (doi:10.1016/S0092-8674(00) 80434-1)
20. Miceli F, Ranelletti FO, Martinelli E, Petrillo M, Scambia G, Navarra P & Ferrandina G 2009 Expression and subcellular localization of CRH and its receptors in human endometrial cancer. Molecular and Cellular Endocrinology 305 6-11. (doi:10.1016/j.mce.2009.02. 013)
21. Minas V, Rolaki A, Kalantaridou SN, Sidiropoulos J, Mitrou S, Petsas G, Jeschke U, Paraskevaidis EA, Fountzilas G, Chrousos GP et al. 2007 Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation. British Journal of Cancer 97 637-645. (doi:10.1038/sj.bjc.6603918)
22. Mukhopadhaya A, Mendecki J, Dong X, Liu L, Kalnicki S, Garg M, Alfieri A & Guha C 2007 Localized hyperthermia combined with intratumoral dendritic cells induces systemic antitumor immunity. Cancer Research 67 7798-7806. (doi:10.1158/0008-5472.CAN-07-0203)
23. Okamoto E, Takagi T, Azuma C, Kimura T, Tokugawa Y, Mitsuda N, Saji F & Tanizawa O 1990 Expression of the corticotropin-releasing hormone (CRH) gene in human placenta and amniotic membrane. Hormone and Metabolic Research 22 394-397. (doi:10.1055/s-2007-1004930)
24. Parham KL, Zervou S, Karteris E, Catalano RD, Old RW & Hillhouse EW 2004 Promoter analysis of human corticotropin-releasing factor (CRF) type 1 receptor and regulation by CRF and Urocortin. Endocrinology 145 3971-3983. (doi:10.1210/en.2004-0194)
25. Rajendran RR & Kao GD 2007 No turning Bax in the combined battle against prostate cancer. Clinical Cancer Research 13 3435-3437. (doi:10.1158/1078-0432.CCR-07-0810)
26. Reed JC 1994 BcI-2 and the regulation of programmed cell death. Journal of Cell Biology 124 1-6. (doi:10.1083/jcb.124.1.1)
27. Reyes TM, Lewis K, Perrin MH, Kunitake KS, Vaughan J, Arias CA, Hogenesch JB, Gulyas J, Rivier J, Vale WW et al. 2001 Urocortin II: amember of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. PNAS 98 2843-2848. (doi:10.1073/pnas.051626398)
28. Schendel SL, Montal M & Reed JC 1998 Bcl-2 family proteins as ionchannels. Cell Death and Differentiation 5 372-380. (doi:10.1038/sj.cdd.4400365)
29. Suda T, Tomori N, Yajima F, Odagiri E, Demura H & Shizume K 1986 Characterization of immunoreactive corticotropin and corticotrophin releasing factor in human adrenal and ovarian tumours. Acta Endocrinologica 111 546-552. (doi:10.1530/acta.0. 1110546)
30. Tao J, Lin M, Sha J, Tan G, Soong TW and Li S 2007 Separate locations of Urocortin and its receptors in mouse testis: function in male reproduction and the relevant mechanisms. Cellular Physiology and Biochemistry 19 303-312. (doi:10.1159/000102393)
31. Tezval H, Jurk S, Atschekzei F, Serth J, Kuczyk MA & Merseburger AS 2009 The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of antiangiogenic signaling pathways. Prostate 69 443-448. (doi:10.1002/pros.20892)
32. Tsatsanis C, Androulidaki A, Dermitzaki E, Charalampopoulos I, Spiess J, Gravanis A & Margioris AN 2005 Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Letters 579 4259-4264. (doi:10.1016/j.febslet.2005.06.057)
33. Vaughan J, Donaldson C, Bittencourt J, Perrin MH, Lewis K, Sutton S, Chan R, Turnbull AV, Lovejoy D, Rivier C et al. 1995 Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 287-292. (doi:10.1038/378287a0)
34. Vivanco I & Sawyers CL 2002 The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nature Reviews Cancer 2 489-501. (doi:10. 1038/nrc839)
35. Walsh S, Gill C, O'Neill A, Fitzpatrick JM & Watson RW 2009 Hypoxia increases normal prostate epithelial cell resistance to receptormediated apoptosis via AKTactivation. International Journal of Cancer 124 1871-1878. (doi:10.1002/ijc.24145)
36. Wang J, Xu Y, Xu Y, Zhu H, Zhang R, Zhang G & Li S 2008 Urocortin's inhibition of tumor growth and angiogenesis in hepatocellular carcinoma via corticotrophin-releasing factor receptor 2. Cancer Investigation 26 359-368. (doi:10.1080/07357900701788106)
37. Wilson BE, Mochon E & Boxer LM 1996 Induction of Bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Molecular and Cellular Biology 16 5546-5556.
38. Yamamori E, Asai M, Yoshida M, Takano K, Itoi K, Oiso Y & Iwasaki Y 2004 Calcium/calmodulin kinase IV pathway is involved in the transcriptional regulation of the corticotropin-releasing hormone gene promoter in neuronal cells. Journal of Molecular Endocrinology 33 539-649. (doi:10.1677/jme.1.01415)